Bide Pharmatech Co (688073.SS) Osake Kurssi

Bide Pharmatech Co Ltd is a pharmaceutical company headquartered in Shanghai, China, operating within the Health Care sector. The company focuses on the research, development, design, production, and sales of drug molecular building blocks, which are essential components in pharmaceutical manufacturing. Its main products include pharmaceutical molecular building blocks and scientific reagents, utilized in various stages of drug development such as target discovery, compound screening, and synthesis optimization. Bide Pharmatech employs 617 full-time staff and completed its initial public offering (IPO) on October 11, 2022. The company serves markets across the Asia Pacific region, India, Europe, and the United States. Its website is https://www.bidepharmatech.com/. The firm's operations are centered on providing specialized chemical solutions for the pharmaceutical industry, supporting the development of new drugs and therapeutic compounds. Bide Pharmatech does not disclose specific details about its founding year, key executives, or acquisition history. Financial figures beyond the employee count and IPO date are not provided in the available information. The company operates as a publicly traded entity under the ticker symbol 688073.SS and ISIN CNE100005NV3. It maintains a presence in multiple global markets, emphasizing its role in the pharmaceutical supply chain as a supplier of critical molecular components.